About AZTherapies, Inc.

Preventing Alzheimer’s disease progression, early

We are at the forefront of the discovery, development and commercialization of novel Alzheimer’s disease therapeutics that will fundamentally improve patient outcomes, quality of life, and disease management. Preventing Alzheimer’s disease progression remains a critical, unmet need for millions of people in the US and worldwide. Our advanced knowledge of Alzheimer’s disease biology, combined with our proprietary scientific discoveries, and clinical and biomarker imaging expertise, provides AZTherapies with unique potential to develop novel therapies to impact Alzheimer’s disease progression.

Our current clinical trial, the Cognite Trial with ALZT-OP1 is testing a simple treatment comprising the novel application of two well-characterized small molecule drugs that block the main triggers of dementia associated with Alzheimer’s Disease: the formation of disease-causing aggregates of amyloid-beta protein oligomers and amyloid plaques; and the neuroinflammatory response responsible for accelerating AD progress. We have also identified several new drug candidates from our ALZT-OP drug pipeline to block disease-causing amyloid-beta aggregation. Our novel solution avoids the problems that have stymied past attempts to develop Alzheimer’s disease-modifying treatments. The availability of drugs to delay the onset of dementia and Alzheimer’s disease will eliminate the anxiety of memory loss, personality changes, and faulty judgement that become progressively worse as the disease progresses.

The drugs used in ALZT-OP1 have a long track record of safety and efficacy for unrelated indications. By discovering new mechanisms of action for these drugs, both with strong safety profiles following years of chronic administration, we can extend their utility to the treatment of Alzheimer’s disease. We completed two Phase I studies in over 50 subjects and launched a multi center worldwide Phase III clinical trials the Cognite Trial with ALZT-OP1 drug combination for disease modifying therapy in persons with early Alzheimer’s disease.

Our drug combination is administered early disease stages where we believe disease progression may be slowed down or halted. Moderate to severe AD disease presents a tremendous challenge—to revert the massive neurodegeneration and compromised state of the brain.